CO-DIAGNOSTICS DL-,001 WKN: A2DU6V ISIN: US1897631057 Kürzel: CODX Forum: Aktien Thema: Hauptdiskussion

Kurs Co-Diagnostics
0,31 EUR
±0,00 % ±0,00
10. Dezember 2025, 23:00 Uhr, Lang & Schwarz
Kommentare 12.220
Neu laden
Anfang
A
Astraman25, 29. Okt 13:41 Uhr
0
Also geht mal alle rein in die U-Bahnen Busse Kneipen und hustet die Menschen an 🤣
A
Astraman25, 29. Okt 13:40 Uhr
0
20€ war der Kurs bei der Pandemie. Wenn wir Glück haben, bekommen wir eine neue Pandemie und dann sind wir reich
A
Astraman25, 29. Okt 13:35 Uhr
0

Hab das Gefühl das du schön.lana genommen wurdest

AMK2020, 29. Okt 13:25 Uhr
Ab ins Igno mit dir
T
ThmsK, 29. Okt 13:31 Uhr
0
Und zurück zu 0,3€. Schöner Pump and Dump.
dynamic
dynamic, 29. Okt 13:31 Uhr
0

Hier geht es nur noch runter!

AMK2020, 29. Okt 13:26 Uhr
💯
dynamic
dynamic, 29. Okt 13:30 Uhr
1

Pumpt gut nach oben

Trading989, 29. Okt 12:50 Uhr
Meintest wohl damit nach unten...🤭
A
Ansel, 29. Okt 13:29 Uhr
1
Es ist echt ein Alptraum
Trading989
Trading989, 29. Okt 13:28 Uhr
0

Lässt euch nicht abmaulen 😊

Trading989, 29. Okt 13:26 Uhr
😃😃😃😃
AMK2020
AMK2020, 29. Okt 13:26 Uhr
2

Zieh an du alte Sau

Trading989, 29. Okt 13:25 Uhr
Hier geht es nur noch runter!
Trading989
Trading989, 29. Okt 13:26 Uhr
0
Lässt euch nicht abmaulen 😊
AMK2020
AMK2020, 29. Okt 13:25 Uhr
0

SALT LAKE CITY, Feb. 21, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that, following a collaborative and informative dialogue with the Food and Drug Administration (FDA), the Company has withdrawn its 510(k) application to the FDA for its Co-Dx™ PCR COVID-19 Test on the PCR Pro™*, in favor of submitting an enhanced version of the test for 510(k) clearance. Co-Dx is pleased with the productive engagement with the FDA related to the initial regulatory submission and with the performance of the test in clinical evaluations, including performance data and functionality of the instrument. The decision by the Company to withdraw the submission was based on discussions with the FDA regarding the ability to detect a potential deterioration of one component of the test, related to shelf-life stability. Following dialogue with the FDA and exploring the various courses of action available, Co-Dx has determined that the best long-term solution would be to submit a version of the test that has been enhanced to address the matter raised in the 510(k) review process.

Astraman25, 29. Okt 12:59 Uhr
Hab das Gefühl das du schön.lana genommen wurdest
Trading989
Trading989, 29. Okt 13:25 Uhr
0
Zieh an du alte Sau
A
Astraman25, 29. Okt 13:00 Uhr
0
The Company plans to submit the next iteration of the Co-Dx PCR COVID-19 test for 510(k) OTC clearance, following the collection of clinical evaluation data to support the new test's performance. A new submission also allows the Company to incorporate more recent Co-Dx PCR platform developments into the COVID-19 test, which Co-Dx believes will also help to create greater operational and manufacturing efficiencies, such as consolidating manufacturing processes to utilize the next generation of test kits and instruments across all tests on the at-home and point-of-care platform. The Company's primary objective is to execute a robust development and commercialization plan for the Co-Dx PCR platform, including ongoing innovations to the PCR Pro instrument. The Co-Dx PCR COVID-19 test is expected to be followed by additional tests for tuberculosis, upper-respiratory multiplex, and a multiplex HPV test, among others. *The Co-Dx PCR platform (including the Co-Dx PCR Home™, Co-Dx PCR Pro™, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is not available for sale.
A
Astraman25, 29. Okt 12:59 Uhr
0
SALT LAKE CITY, Feb. 21, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that, following a collaborative and informative dialogue with the Food and Drug Administration (FDA), the Company has withdrawn its 510(k) application to the FDA for its Co-Dx™ PCR COVID-19 Test on the PCR Pro™*, in favor of submitting an enhanced version of the test for 510(k) clearance. Co-Dx is pleased with the productive engagement with the FDA related to the initial regulatory submission and with the performance of the test in clinical evaluations, including performance data and functionality of the instrument. The decision by the Company to withdraw the submission was based on discussions with the FDA regarding the ability to detect a potential deterioration of one component of the test, related to shelf-life stability. Following dialogue with the FDA and exploring the various courses of action available, Co-Dx has determined that the best long-term solution would be to submit a version of the test that has been enhanced to address the matter raised in the 510(k) review process.
AMK2020
AMK2020, 29. Okt 12:57 Uhr
0

Pumpt gut nach oben

Trading989, 29. Okt 12:50 Uhr
Sag mal bist du mit dem Egon verwandt?
AMK2020
AMK2020, 29. Okt 12:56 Uhr
0
Alle die auf lana stehen dürfen sich gleich freuen ☝🏻
Meistdiskutiert
Thema
1 RHEINMETALL Hauptdiskussion -2,85 %
2 BTC/USD Hauptdiskussion +0,09 %
3 VONOVIA Hauptdiskussion -0,06 %
4 SOLAREDGE TECH Hauptdiskussion +4,30 %
5 Strategy B -2,30 %
6 Der Gold Club von Susiwong +0,12 %
7 NVIDIA Hauptdiskussion -0,64 %
8 NioCorp Developments -5,10 %
9 DRONESHIELD LTD Hauptdiskussion +19,34 %
10 NEL ASA Hauptdiskussion -1,43 %
Alle Diskussionen
Aktien
Thema
1 RHEINMETALL Hauptdiskussion -2,85 %
2 VONOVIA Hauptdiskussion -0,06 %
3 SOLAREDGE TECH Hauptdiskussion +4,30 %
4 Strategy B -2,30 %
5 NVIDIA Hauptdiskussion -0,64 %
6 NioCorp Developments -5,10 %
7 DRONESHIELD LTD Hauptdiskussion +19,34 %
8 NEL ASA Hauptdiskussion -1,43 %
9 Ecograf - ein Stern am Graphithimmel -1,11 %
10 ALPHABET Hauptdiskussion +0,99 %
Alle Diskussionen